https://www.marketscreener.com/quote/stock/HUTCHMED-CHINA-LIMITED-59660104/news/HUTCHMED-China-The-pivotal-Phase-III-SANET-p-trial-demonstrated-surufatinib-reduced-risk-of-progre-35658101/?utm_source=telegram&utm_medium=social&utm_campaign=share